EGFR and non-small cell lung carcinoma: These results indicate that the Gefitinib‐untargetable EGFR signaling pathway is active in EGFR T790M/L858R NSCLC cells, and important for the survival of EGFR mutated but less so for EGFR wild‐type cells.